Micrus Endovascular (MEND)

TOP CONTRIBUTORS

Tom Park

www.zacks.com

Micrus Endovascular Corporation develops, manufactures, and markets both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. These products are used by interventional neuroradiologists and neurosurgeons primarily to treat cerebral aneurysms responsible for hemorrhagic stroke. Micrus in March 2006 launched the Pharos stent, the first of its line of products designed to treat ischemic disease. Hemorrhagic and ischemic stroke are both significant causes of death and disability worldwide. The company's product lines in treating cerebral aneurysms consist of endovascular systems that enable a physician to gain access to the brain in a minimally invasive manner through the vessels of the arterial system. Micrus believes these products provide a safe and reliable alternative to more invasive neurosurgical procedures. The company's proprietary three-dimensional, embolic coils are unique in that they automatically and rapidly deploy within an aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also supplies access devices and products including microcatheters and guidewires used to deliver microcoils and stents for the treatment of cerebral vascular disease. The company's revenue is derived primarily from sales of microcoils. Based on geography, customers in the Americas, Europe, and Asia Pacific over the twelve months ended March 31, 2007 contributed 54%, 30%, and 16%, respectively to total revenue. On June 21, 2005, Micrus completed an initial public offering of its common stock.

References